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S U M M A R Y
Enterococci are implicated in less than 2.3% of prosthetic joint infections. These infections can be difﬁcult
to treat and therapeutic failures are not uncommon. In these situations, daptomycin is a safe and
effective alternative. We present a clinical case with a successful response to the prolonged use of high-
dose daptomycin.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/3.0/).
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Prosthetic joint infection (PJI) is a serious complication of
prosthetic joint implantation. Gram-positive bacteria, particularly
Staphylococcus spp, are the most relevant microorganisms, and
enterococci are involved in 2.3% of cases.1
In penicillin-susceptible microorganisms and in the absence
of high-level resistance to aminoglycosides, the preferred
treatment for Enterococcus faecalis infections is the combination
of ampicillin and aminoglycoside. Daptomycin is a novel
cyclic lipopeptide antibiotic that exhibits a rapid bactericidal
concentration-dependent action, killing cells through mem-
brane lysis. It is considered an alternative therapeutic option
for PJI.2
We present a case of Hip PJI caused by E. faecalis treated with
daptomycin at high doses (10 mg/kg/day) for a prolonged time
(12 weeks), describe the safety of this treatment option, and
discuss its possible relationship to successful clinical response.* Corresponding author. Tel.: +34 948 255 400; fax: +34 948 296 500.
E-mail address: jryuste@unav.es (J.R. Yuste).
http://dx.doi.org/10.1016/j.ijid.2014.05.034
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).2. Case report
A 42-year-old male with avascular necrosis of the femoral head
was admitted to our clinic for a right total hip arthroplasty. Eight
months later, the patient experienced local pain. Ultrasound
examination showed inﬂammation of the subcutaneous tissue and
small hypoechogenic areas with liquid material. Bacteriological
cultures of aspirated material were negative. He received empirical
treatment with vancomycin and continued with levoﬂoxacin as an
outpatient.
Two months later, he described local pain again and a palpable
mass lesion in the surgical area. Multiple ultrasound-guided
needle biopsies were taken and histological analysis showed a
tumour with necrotic material. The patient was admitted for
tumour extirpation, and multiple intraoperative biopsies were
obtained. He developed a fever shortly after surgery. Gram staining
revealed Gram-positive cocci, and empirical treatment with co-
trimoxazole was started. Histological analysis showed granuloma-
tous inﬂammation, central necrosis, and giant multinucleated
cells. Ziehl–Neelsen and Grocott stains, PCR for Mycobacterium
tuberculosis, and mycological and mycobacterial cultures were
negative. Bacteriological cultures revealed E. faecalis susceptible to
ampicillin, and antibiotics were changed to ampicillin plus
ceftriaxone.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
Table 1
Patients with prosthetic joint infection due to Enterococcus spp treated with daptomycin
Author [reference], year Prosthesis
type
Type of
infection
Microorganism Daptomycin dosage
(mg/kg/day)
Total
antibiotics
Outcome Follow-up
(years)
Rasouli et al. [1], 2012 Hip - E. faecalis - 4–6 weeksa Controlled 1.5
Rasouli et al. [1], 2012 Hip - E. faecium - 4–6 weeksa Controlled 3.2
Rasouli et al. [1], 2012 Hip - E. faecium - 4–6 weeksa Controlled 2.8
Corona et al. [5], 2012 THA IIb Enterococcus spp 6 37 days Failurec 1.1
Corona et al. [5], 2012 THA IIb Enterococcus spp 7 56 days Success 1
Yuste et al., 2014 Hip IIb E. faecalis 10 84 days Success 3.5
Hip,; THA, total Hip arthroplasty.
a Speciﬁc duration not speciﬁed in the article.
b According to the Tsukuyama classiﬁcation.
c Need for subsequent infection-related surgery for persistence or relapse of infection or the need for suppressive antibiotic therapy.
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purulent discharge from the incision. A surgical scrub was done
and antibiotics were substituted for linezolid. After 13 days of
treatment, the patient had persistent local signs of infection and
synovial involvement appeared. Surgical debridement and socket
exchange were done and four periprosthesis biopsies and a sample
of synovial ﬂuid were taken. The joint ﬂuid sample and three
separate biopsy specimens yielded E. faecalis. The patient’s platelet
count decreased to 110  109/l after a previous count of 293  109/
l. After 4 weeks of treatment, his therapy was changed to
daptomycin at a dose of 10 mg/kg/day.
The patient remained hospitalized for 10 days after daptomycin
was started. He was discharged with daily dosing as an outpatient. A
totally implantable vascular access device was placed to avoid
recurrent peripheral phlebitis, which appeared during follow-up. He
completed 12 weeks of treatment. Clinical success was observed and
no relapse has occurred after 39 months of follow-up.
3. Discussion
There are limited data about prosthetic infections due to
enterococci and these are frequently found as part of a
polymicrobial infection.1,2 In this case, we identiﬁed the pathogen
in three periprosthetic biopsies and in two joint ﬂuid samples,
which conﬁrmed its direct involvement in the infection.
Some authors recommend a penicillin–aminoglycoside combi-
nation as the therapy of choice. Ampicillin plus ceftriaxone has
been postulated as an alternative in the treatment of PJI, with a
cure rate of 90%, despite being managed with the retention of the
foreign material.3 The ampicillin–ceftriaxone combination repre-
sented our preferred therapeutic option, but was discontinued
because of clinical and microbiological failure.
Linezolid, an oxazolidinone, has also been used in patients with
bone infections and PJIs with Gram-positive microorganisms
including enterococci. Oral and intravenous administrations are
bioequivalent, facilitating outpatient treatment. However the risk
of haematological adverse events limits its use. In this case, after
4 weeks of treatment, linezolid was discontinued because of
adverse events and persistent infection.
Daptomycin, a cyclic lipopeptide antibiotic with potent activity
against Gram-positive bacteria, has a rapid bactericidal concentra-
tion-dependent action that kills cells through membrane lysis. The
calculated cumulative fraction of response against E. faecalis is 38% at
4–6 mg/kg/day and 96% at 8–12 mg/kg/day. It has a bactericidal effect
against planktonic and stationary-phase microorganisms, which
explains its good activity in bioﬁlms. The addition of gentamicin does
not enhance the mean area under the curve (AUC) for enterococcal
isolates, thus not improving the bactericidal effect.2
Daptomycin has been shown to be safe at initially approved and
higher doses (up to 12 mg/kg/day), and in prolonged therapy.4Myopathy and rhabdomyolysis with increased creatinine phos-
phokinase is the most common side effect (3–7%). Other adverse
events including neuropathy and eosinophilic pneumonia have
been described.
In this patient, serum creatinine phosphokinase levels before
the initiation of daptomycin and weekly during treatment were
persistently normal. The only reported adverse event was repeated
peripheral phlebitis, so a totally implantable vascular access device
was placed. After 12 weeks, daptomycin was discontinued and the
catheter was removed.
It is important to consider the risk of recurrence of phlebitis or
catheter-related infections. In these cases, the placement of a
permanent central venous catheter should be evaluated, especially
when the treatment is expected to last longer than 30 days, as in
the present case.
After surgical debridement with partial prosthesis retention
and based on pharmacokinetic/pharmacodynamic parameters and
safety studies, our choice was daptomycin monotherapy at 10 mg/
kg/day for 12 weeks as rescue therapy because of previous
antibiotic treatment failure.
Published clinical experience in treating prosthesis-associated
enterococcal joint infections with daptomycin is limited to ﬁve
cases, two of which described clinical cure (Table 1).1,5
This is the ﬁrst published case to show the clinical efﬁcacy and
safety of treatment with a high dose of daptomycin (10 mg/kg/day)
over a prolonged time (12 weeks) in a patient with a PJI caused by
E. faecalis. Although daptomycin is not the initial drug of choice for
PJI, it should be considered as a valid therapeutic option given its
potent bactericidal activity maintained in bioﬁlms, its good safety
proﬁle, and the possibility of administration on an outpatient basis.
Randomized prospective clinical trials are needed.
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